Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts had expected as the drugmaker prepares for the loss of exclusivity of several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results